---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-040956"
form_type: "8-K"
ticker: "GLUE"
cik: "0001826457"
company_name: "Monte Rosa Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:58:29.396532+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Monte Rosa Q2 net loss $35.2M, CFO resigns; cash sustains into 2025

## Summary
- Net loss of $35.2M for Q2 2023 vs $26.5M in Q2 2022; R&D expenses $29.1M.
- Cash and marketable securities $207.6M at June 30, expected to fund operations into 2025.
- CFO Ajim Tamboli resigned; no replacement announced yet.
- Initial Phase 1/2 data for MRT-2359 expected H2 2023; IND for MRT-6160 expected H1 2024.
- FDA Orphan Drug Designation for MRT-2359 for small cell lung cancer received.

## SEC filing metadata
- accession: 0000950170-23-040956
- form_type: 8-K
- ticker: GLUE
- cik: 0001826457
- company_name: Monte Rosa Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826457/000095017023040956/0000950170-23-040956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826457/000095017023040956/glue-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-040956
- JSON: https://secwatch.observer/filing/0000950170-23-040956.json
- Plain text: https://secwatch.observer/filing/0000950170-23-040956.txt

## Key facts
- Earnings Releases
  Monte Rosa Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income $35.2 million.
  - Period: the quarter ended June 30, 2023
  - Net income: $35.2 million
  - Result: reported results
  source text: Net loss for the second quarter of 2023 was $35.2 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826457/000095017023040956/0000950170-23-040956-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.